The deal intelligence layer
for biotech and pharma VCs.
Pro for every portfolio company. Plus the fund-level intelligence layer your operating partner actually opens — quarterly benchmarking reports, dedicated analyst hours, cross-portfolio partner matching, and a live admin dashboard.
5-seat Growth tier — annual billing
Active Companies
9
+2 vs LQ
Comps Pulled
347
this month
Deal Memos
24
generated
Active Deals
6
in negotiation
Therapeutic Area Concentration
Onc
Neu
Imm
Met
Rare
Card
Hem
Inf
Oph
Der
GI
WH
3 portfolio companies clustering in Oncology — coordination opportunity flagged
Your portfolio companies are negotiating
every deal with one hand behind their back.
They negotiate against anecdote, outdated databases, and outside counsel billing $1,500/hour for incomplete benchmarks. A single mispriced Phase 2 licensing deal costs $5–20M in foregone upfront — every quarter, in every TA, across every fund.
Below-market upfront — every time
No visibility into market-rate terms for their stage and TA. Companies accept upfronts 15–30% below comparable deals because they have no quantitative basis for counter-proposals.
Milestone structures that leak NPV
Milestone allocations that undervalue clinical and regulatory achievements relative to comparable transactions — costing $2–8M in NPV per deal that nobody sees on the term sheet.
40+ wasted hours per deal
BD teams spend 40+ hours assembling manual comps from press releases and SEC filings instead of structuring the negotiation. Time is the most expensive line item.
The Portfolio License costs less per year than one hour of outside counsel at a top-tier life sciences law firm.
“I've spent every quarter for the last three years watching portfolio companies leave money on the table because they didn't have benchmarks the partner across the table did. Outside counsel charges $15,000 per deal to assemble comps that take our platform 30 seconds. The Portfolio License is what I wanted at every fund I've worked with — institutional deal intelligence as portfolio infrastructure, not as an expense line.”
Issa Kildani
Managing Partner · Ambrosia Ventures
One platform. Three fund stages.
Whether you're deploying Fund I or coordinating 20+ portfolio companies, there's a tier built for your operating cadence.
Emerging Managers
Fund I–II · 3–5 portfolio companies
Your first operating partner hire needs leverage — not more spreadsheets. Growth gives every portfolio company institutional-grade benchmarks for less than 10% of an analyst FTE.
View Growth tierActive Mid-Stage Funds
Fund III–IV · 8–12 portfolio companies
You have the portfolio density where cross-company coordination matters. Scale delivers 5 hours/month of dedicated analyst time and the visibility layer that prevents two companies from chasing the same partner uncoordinated.
View Scale tierInstitutional Funds & CVCs
15+ portfolio companies · Complex org structures
You need white-glove service, a named analyst who knows your portfolio, and a quarterly strategy call with our Managing Partner. Enterprise is built for procurement teams that demand SSO, DPAs, and audit trails.
View Enterprise tierEvery seat unlocks the full Pro platform
14 calculation engines. 12 therapeutic areas. 1,900+ transactions. No feature gates between portfolio companies.
Deal Benchmarking
1,900+ transactions
rNPV Modeling
TA-specific PoS curves
Monte Carlo
10,000-iter simulations
AI Deal Memos
Institutional-quality
Partner Matching
850+ companies, 10-factor
Buyer-Specific
Up to 3 buyers compared
Scenario Analysis
Bear / Base / Bull
Branded PDFs
White-labeled exports
What the operating
partner gets.
16 capabilities your portfolio companies will never see — the reason operating partners renew. Organized in five categories, each addressing a specific pain point operating partners deal with daily.
Know which portfolio company is in deal mode — without asking the CEO.
A read-only command center for the operating partner. See which companies are actively benchmarking, what comps they're pulling, and where deal activity is concentrating across the portfolio. The visibility you needed without the awkward Friday afternoon CEO check-in.
- Live activity feed of portfolio benchmarking sessions
- Per-company engagement metrics for LP reporting
- Therapeutic area heatmap showing deal-comp clustering
- Pooled seat management — reassign instantly as the portfolio evolves
sessions
18
comps
87
memos
4
sessions
12
comps
54
memos
3
sessions
9
comps
41
memos
2
sessions
7
comps
32
memos
2
sessions
4
comps
18
memos
1
sessions
2
comps
9
memos
0
Your next LP letter, partially written by us.
A bespoke benchmarking report assembled by the Ambrosia Ventures advisory team. Customized to the fund's specific portfolio composition. Includes a 2-page LP executive summary written for inclusion in your quarterly LP letter — saving the operating partner a week per quarter.
- Portfolio-wide deal landscape with year-over-year trends
- 5–10 most relevant comps per active portfolio company
- Market positioning analysis — flagging under-benchmarked programs
- LP executive summary suitable for inclusion in quarterly letters
Q2 2026 · Portfolio Benchmarking Report
Atlas Bio Capital
Prepared by Ambrosia Ventures · 24 pages
Upfront % of Total Deal — Portfolio vs Market
Flagged: NeuralPath upfront tracking 17pts below market for Phase 1 neuro deals.
When two portfolio companies chase the same partner, you'll know before they do.
Ambrosia Ventures monitors deal flow across all portfolio companies and proactively identifies intra-portfolio synergies, competitive overlap, and warm partnering introductions — surfaced via monthly digest with ad hoc alerts for time-sensitive opportunities.
- Intra-portfolio synergy detection (complementary assets, target overlap)
- Competitive overlap alerts when companies pursue the same partner
- Warm introduction pipeline via Ambrosia Ventures advisory network
- Each intro includes a brief deal thesis memo
Intra-Portfolio Synergy
OncoVista + CellGenix
Complementary ADC payload + cell therapy delivery platform. Co-development opportunity.
Competitive Overlap
3 companies pursuing AstraZeneca
OncoVista, MetaboRx, and CellGenix all targeting AZN BD. Coordination recommended.
Warm Intro Available
NeuralPath Bio → Roche Neurology
Roche head of Neuroscience BD warm to bispecific antibody platforms. Thesis memo attached.
Every relevant comp, the day it's filed — routed to the right portfolio company.
Configurable per portfolio company by therapeutic area, modality, or development stage. Each alert includes an AI-generated relevance summary explaining why the transaction is comparable. Delivered as a consolidated weekly digest to the operating partner.
- Per-company alert configuration with TA + modality tags
- Direct link to the full deal comp in the platform
- AI-generated 3-sentence relevance summary for every alert
- Consolidated weekly digest across the entire portfolio
Pfizer / Vanguard Bio · ADC · P2
Roche / Acelyrin · Bispecific · P1
Novartis / CellGenix Tx · CAR-T · P3
Eli Lilly / Camurus · GLP-1 · P2
Five categories. Every operating partner pain point.
We started with the four most-asked-for features. Then we built twelve more — to make Portfolio License the only deal intelligence platform sophisticated VC firms need.
Visibility & Coordination
Real-time portfolio intelligence — without the awkward CEO check-ins.
3 capabilities
Admin Dashboard
Live activity feed, engagement metrics, TA heatmap, seat management
Cross-Portfolio Deal Pipeline Tracker
Active deal conversations across the portfolio + conflict detection when two cos chase the same partner
Cross-Portfolio Partner Matching
Synergies, overlap alerts, warm introductions via Ambrosia advisory network
Intelligence Delivered
Bespoke content the operating partner ships forward — to LPs, boards, and portfolio CEOs.
4 capabilities
Quarterly Portfolio Report
LP-ready, bespoke per fund — assembled by the Ambrosia advisory team
Fund-Branded White-Label Reports
Every deliverable comes out with your fund's logo, color palette, and disclaimers
Shared Fund Comp Library
Saved comp sets, peer sets, and annotations that compound across the fund
Negotiation Playbook Library
Term sheet templates and counter-proposal frameworks drawn from 1,900+ real deals
Workflow & Alerts
Built into where operating partners actually work — no new tab required.
3 capabilities
Deal Alert Feeds
Per-portfolio-company alerts with AI relevance summaries; weekly consolidated digest
Custom Alert Rules
Power-user filtering: "alert me when AstraZeneca does another bispecific deal"
Slack & Teams Integration
Native push to where operating partners already live
Concierge Service
Trusted advisor relationship, not a software vendor relationship.
3 capabilities
Dedicated Analyst Hours
2–10 hours/month of bespoke analyst time, delivered as fund-branded reports within 5 business days
Portfolio Company Office Hours
Quarterly 30-min slots with seasoned Ambrosia BD veterans — your portfolio CEOs get on-demand expertise
Annual Customer Summit
Half-day curated event during JPM/BIO — operating partners only, peer roundtables, named pharma BD heads
Enterprise Infrastructure
Built for procurement, IT, and legal review — not as an afterthought.
3 capabilities
SSO / SAML + Audit Logs
Okta, Azure AD, Google Workspace. Per-seat audit logs. IP allowlisting.
API Access
Read-only REST API for funds with internal data warehouses or custom dashboards
Custom DPA + Security Docs
Pre-built security questionnaire responses + biotech-VC-appropriate DPA template
Built on the platform used by 850+ biopharma BD professionals.
Portfolio License is the multi-seat extension of the Ambrosia Ventures Deal Calculator — the same database, same engines, same 1,900+ transactions trusted by individual BD pros at every major biotech and pharma. Your portfolio companies aren't getting a separate product — they're getting the institutional version of what their counterparts at Pfizer, Merck, and Sanofi already use.
1,900+
Verified transactions
850+
BD pros on platform
12 TAs
Therapeutic areas covered
14
Calculation engines
Pricing built for fund stage
Every tier includes the full fund-level intelligence layer. Higher tiers unlock more analyst hours, more seats, and Enterprise-exclusive concierge services.
Growth
5 seatsFor emerging managers
Built for Fund I–II biotech VCs. Equip your first 5 portfolio companies for less than 10% of an analyst FTE.
$30,000 billed annually
Included
- 5 Pro seats (pooled, reassignable)
- 2 hrs/mo dedicated analyst time
- All 16 fund-level capabilities
- Admin dashboard + pipeline tracker
- Quarterly portfolio benchmarking report
- SSO/SAML, audit logs, custom DPA
- 4-week dedicated onboarding
Scale
10 seatsThe institutional standard
For mid-stage funds actively coordinating partnering across 8–12 portfolio companies.
$60,000 billed annually
Included
- 10 Pro seats (pooled, reassignable)
- 5 hrs/mo dedicated analyst time2.5x Growth
- All 16 fund-level capabilities
- White-label reports + shared comp library
- Slack & Teams integration
- Negotiation playbook library
- 4-week dedicated onboarding
Enterprise
15+ seatsWhite-glove for institutional funds
For institutional funds and pharma CVCs with deep portfolios requiring named analyst coverage and Managing Partner access.
$120,000 billed annually
Included
- 15+ Pro seats (pooled, reassignable)
- 10 hrs/mo + named analyst5x Growth
- All 16 fund-level capabilities
- Everything in Scale, plus:
Enterprise exclusive
- Quarterly strategy call with Managing Partner
- 15% advisory preferred rates
- 2-hr strategic assessment per portfolio co
Pooled seats — reassign across portfolio companies at any time. Custom seat counts available for funds with 20+ portfolio companies. Dedicated analyst hours roll over within the contract year.
Three capabilities reserved for
Enterprise funds.
The difference between a software subscription and a trusted advisory relationship.
Quarterly Strategy Call
With Managing Partner
A quarterly 60-minute session with Issa Kildani. Review portfolio-wide deal activity, calibrate benchmarking priorities for the next quarter, and get strategic guidance on your highest-priority transactions.
Named Analyst
10 hrs/mo dedicated
Your fund gets a named analyst who learns your portfolio, your TAs, and your LP reporting cadence. Not a help desk ticket — a relationship. Bespoke reports delivered within 5 business days.
Advisory Preferred Rates
15% discount
Enterprise customers receive 15% preferred rates on all Ambrosia Ventures advisory engagements — from deal-specific benchmarking reports to board-level strategic assessments.
Earn it back on a single
milestone payment.
The Scale tier costs $60,000/year. A single Phase 2 licensing deal carries $200–500M in total deal value across upfront, milestones, and royalties. The math is unkind to anyone choosing the alternative.
Annual cost (Scale tier, 10 seats)
$60,000
Average Phase 2 total deal value (incl. milestones)
$200–500M
Improvement needed to break even
0.012–0.030%
Realistic deal optimization with better benchmarks
$5–20M+
Implied ROI
83–333x
Doesn't account for reduced outside counsel hours ($15–25K per transaction), faster deal timelines, or improved LP reporting.
What $60,000/year is also less than
Replaces a category of spending biotech VCs already make — at less than half the price of comparable enterprise platforms (Cortellis, Evaluate Pharma, Capital IQ), with deeper deal-mechanics specialization than any of them.
Legacy platforms weren't built for deal mechanics.
Broad pharmaceutical databases cover pipeline and financials. Ambrosia covers the negotiation layer — upfronts, milestones, royalties, and partner matching.
Pricing based on publicly available information and industry benchmarks. Actual pricing may vary by contract and configuration.
Compare every tier
Pro is for the dealmaker. Portfolio is built for the firm.
Scroll right to compare all tiers →
From contract signed to first quarterly report — 30 days.
Dedicated white-glove onboarding for the operating partner and every portfolio company.
Fund Setup
Admin dashboard provisioned. Portfolio roster configured with TA tags. Seat allocation, SSO, and deal alert preferences set per company.
Company Onboarding
30-minute walkthrough with each portfolio company's BD or C-suite lead. First deal comp report generated live to demonstrate immediate value.
Partner Profiles
Custom partner matching profiles built for each company. Cross-portfolio synergy scan completed. Deal alert feeds activated. Negotiation playbook library curated for your TAs.
Baseline Report
Initial portfolio benchmarking snapshot delivered. Operating partner review call to calibrate report cadence and analyst hour usage.
Information barriers between every portfolio company
Every portfolio company seat is isolated. The admin dashboard shows aggregate activity only — never individual search queries or proprietary analysis.
Seat Isolation
Company A cannot view Company B's searches, saved comps, or deal memos. Hard partition at every layer.
Encryption Everywhere
AES-256 encryption at rest, TLS 1.3 in transit. Hosted on Vercel with Supabase backend.
SOC 2 + Custom DPA
SOC 2 Type I roadmap in progress. Pre-built security questionnaire responses + biotech-VC-appropriate DPA template.
Data Portability
All portfolio company data exportable on request. 90-day post-termination retention with full export support.
Database integrity: 1,900+ verified biopharma licensing, partnering, and M&A transactions sourced from SEC 8-K filings, FTC premerger filings, press releases, clinical trial registries, and proprietary Ambrosia Ventures deal intelligence. New transactions added within 5 business days of public disclosure.
Frequently asked questions
Everything your procurement team will ask — answered upfront.
Can we modify or cancel our contract?
All Portfolio License contracts are billed annually. Seats are pooled and reassignable at any time from the admin dashboard. We offer a 30-day written notice provision for tier downgrades at renewal. No mid-term cancellations — but the math on keeping it is pretty compelling (see the ROI section above).
How is portfolio company data kept separate?
Every portfolio company seat is fully isolated. Company A cannot view Company B's searches, saved comps, deal memos, or any proprietary analysis. The admin dashboard shows aggregate activity only — never individual search queries. All data is encrypted AES-256 at rest and TLS 1.3 in transit.
How long does onboarding take?
Four weeks from signed contract to first quarterly report. Week 1: fund setup and SSO configuration. Week 2: 30-minute walkthrough with each portfolio company. Week 3: partner profiles, alert feeds, and playbook curation. Week 4: baseline portfolio benchmarking snapshot delivered.
Do unused analyst hours roll over?
Yes — within the contract year. Unused hours from Q1 can be used in Q2–Q4. Hours do not carry over to the next annual contract. We find most funds use their full allocation once the analyst learns their portfolio composition.
Can we add or reassign seats mid-contract?
Yes. All seats are pooled across the portfolio. Add new seats at the per-seat rate for your tier at any time. Reassign existing seats between portfolio companies instantly from the admin dashboard — no support ticket needed.
Do you support custom integrations?
API access is included in all portfolio tiers. We offer a read-only REST API for funds with internal data warehouses or custom dashboards. Slack and Microsoft Teams integrations are native. For deeper integrations, we scope custom work through advisory engagements.
What about multi-fund or family office pricing?
Contact us directly. We offer cross-fund seat sharing, consolidated reporting across multiple funds, and custom pricing structures for family offices and multi-strategy platforms. Enterprise tier required for multi-fund configurations.
How does this compare to Cortellis or Evaluate Pharma?
Cortellis ($120K+) and Evaluate Pharma ($40–60K/seat) are broad pharmaceutical databases. Ambrosia is purpose-built for deal mechanics — upfronts, milestones, royalties, partner matching, and negotiation benchmarks. We go deeper on the partnering and licensing layer while costing 50–75% less. They're complementary tools, but Ambrosia covers the deal intelligence gap those platforms don't address.
From contract signed to first
quarterly report — 30 days.
15-minute demo with a personalized walkthrough using comps relevant to your portfolio's lead programs. Onboarding begins within 5 business days of executed agreement.
Issa Kildani · Managing Partner · Ambrosia Ventures